Polymer-drug conjugates: recent development in clinical oncology - sprookjes - yvandenbroek - TriplyDB

Polymer-drug conjugates: recent development in clinical oncology

Polymer-drug conjugates: recent development in clinical oncology

http://www.wikidata.org/entity/Q34656003

about

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma Nanotechnology: Future of Oncotherapy Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery Polymer-drug conjugates: origins, progress to date and future directions Cytokines as biomarkers of nanoparticle immunotoxicity Probing the binding sites of antibiotic drugs doxorubicin and N-(trifluoroacetyl) doxorubicin with human and bovine serum albumins Clinical Translation of Nanomedicine.Polymeric Nanostructures for Imaging and Therapy Near-infrared light modulated photothermal effect increases vascular perfusion and enhances polymeric drug delivery.Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery.Poly(ethylene oxide)-block-polyphosphoester-graft-paclitaxel conjugates with acid-labile linkages as a pH-sensitive and functional nanoscopic platform for paclitaxel delivery Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release.Advancement and prospects of tumor gene therapy Co-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells.Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery.Biocompatible nanopolymers: the next generation of breast cancer treatment?CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy In vivo magnetic resonance imaging of tumor protease activity.Poly(ethylene oxide)-block-polyphosphester-based Paclitaxel Conjugates as a Platform for Ultra-high Paclitaxel-loaded Multifunctional Nanoparticles.Macromolecular therapeutics Prodrug applications for targeted cancer therapy.Prodrugs for improving tumor targetability and efficiency.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Conscripts of the infinite armada: systemic cancer therapy using nanomaterials.Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents.FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.POLYMERIC BIOMATERIALS AND NANOMEDICINES.PEGylation as a strategy for improving nanoparticle-based drug and gene delivery Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide).Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.Chain-shattering polymeric therapeutics with on-demand drug-release capability Multifunctional micellar nanomedicine for cancer therapy.A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic.Biodegradable polydepsipeptides.Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.Molecules that modulate Apaf-1 activity.Nanoparticles containing insoluble drug for cancer therapy.Clinical developments in nanotechnology for cancer therapy.Polymer-drug conjugates for novel molecular targets.

P2860

Q26744830-921F28D2-E14C-4FC3-9D8F-2D58CE3903BE Q26801067-62E05028-50AF-4590-8552-FA5843181F78 Q26852723-AA817063-0A7C-4C77-AA4D-3A144F88DAB5 Q27002505-0850AD67-B849-4480-B25D-6E186805F571 Q28383550-F5A9384D-9983-43B4-A334-78AC52C2F76B Q28482550-43FF158A-FCB2-4FF1-8CE4-5F969CFBBA3C Q30355939-CA20B3B9-D2E4-4789-B276-040A2714AC0B Q30372383-63FC15EC-6047-4101-8D1D-46EA93AD8401 Q30459975-320C3345-C61C-4DB6-A903-D7820E0C482F Q30465439-0328615E-EB2D-480F-A2DE-64556776BC48 Q30664584-2B0DED58-6DAB-41DC-87D9-553172839CBA Q33528045-358EB15F-E2EF-488D-A3E3-6EE26A9F9CAA Q33579330-750BA003-25B9-44DF-9C4B-228E8AD7F0EB Q33634653-25D99557-ADEC-4953-9F2C-2D00C7289DC9 Q33836864-4B7EB5C3-3C9D-4A40-AC5F-C06A45E8ABE2 Q33864065-876A0D7B-6BF5-4929-8809-D410C444DA1D Q33993634-95745C16-A98C-4197-AD60-92B42C1B940E Q34048774-80D7B55E-2E56-46FD-B0F7-58799A5B6E4B Q34069122-2476C6BA-2DAD-4D96-9674-C7B6BA226B56 Q34079574-1C1B4880-7521-41DD-B7CC-F3A9F3A96F2E Q34099780-9111436C-AE4F-4A98-A55A-FA6A005BE198 Q35095165-E3999D79-13F0-4039-8CCF-2914F90EEA0C Q35168703-70DBF237-1409-4E9E-937F-6CBCEB1DE818 Q35545342-E0D008A5-B6D6-4597-844D-99D3A8A56B2A Q36214907-4475B5FB-B3E4-4631-AF80-5D81944A56D6 Q36244719-C0D8FDCE-7EBA-4205-96C6-F00FD292B8CD Q36376467-D663AB2E-2EF7-4CAC-9599-D7FEF1E8A778 Q36703361-4F78BC73-4B08-4EF1-94F5-D397E7A7A349 Q37056787-2387EBCD-C885-4971-9C2E-6EF3E246D191 Q37151600-054E4A5C-34A0-481F-AD67-A84FF20F6E91 Q37240107-A7D44748-9AF3-4986-8258-55E443120F66 Q37344163-C5520C90-FE79-4967-B496-5D14F34C471E Q37393951-A67E00E2-BB4E-484C-8899-19C8F9EB8B35 Q37427408-5BCACCEA-D769-4E4E-9A1F-CEB92B5C2EA0 Q37444094-1A16992A-1F2B-4AA8-99BC-B8FC80458517 Q37476252-C80929E1-5F3A-4B9F-BE90-C1808E03805A Q37680800-678E9B69-42C5-4FA9-8C63-B6C00C0AD227 Q37693046-2E9B328C-EE41-4F56-8DB1-7DBFC5BC1059 Q37765187-AF4511E8-F990-424A-98F8-E221D64BD6BD Q37782076-777F6009-54FB-4E54-83FC-A71B2FD29733

P2860

Polymer-drug conjugates: recent development in clinical oncology

http://www.wikidata.org/entity/Q34656003

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Polymer-drug conjugates: recent development in clinical oncology

@ast

Polymer-drug conjugates: recent development in clinical oncology

@en

Polymer-drug conjugates: recent development in clinical oncology

@nl

type

label

Polymer-drug conjugates: recent development in clinical oncology

@ast

Polymer-drug conjugates: recent development in clinical oncology

@en

Polymer-drug conjugates: recent development in clinical oncology

@nl

prefLabel

Polymer-drug conjugates: recent development in clinical oncology

@ast

Polymer-drug conjugates: recent development in clinical oncology

@en

Polymer-drug conjugates: recent development in clinical oncology

@nl

P1433

Q34656003-AA1F3E6B-F8C6-4FEE-97E2-D51C4B7A5CFD

P1476

Q34656003-6D3E8D31-96A6-4D82-8B54-AEE7E9644E38

P2093

Q34656003-52AF8C05-486F-48C5-90B2-C5EAB6D0D2A5

Q34656003-75BFEC6C-7C92-42D0-96A0-671912923C6F

P2860

Q34656003-025EF71E-F0FA-4A80-8A6A-E68047046962

Q34656003-0EFAF748-F525-4898-8BCA-FEF09199D415

Q34656003-11AEFD1E-6C93-411D-B2B9-A8A16FCBCC3D

Q34656003-1AF0E217-4B69-4779-818B-AF981938FD86

Q34656003-1B87EBE0-B831-49CA-AD89-55A36A53AC25

Q34656003-1C8C1E80-4C63-4DE6-ACDA-7E37F3A9DBEB

Q34656003-25D1013A-43EA-46F2-B7C5-1CB6DC8E20FD

Q34656003-2825AD6E-91B0-4729-B335-B1A4BDE11363

Q34656003-30BD706B-446E-420A-B845-7C8EAE26955C

Q34656003-318E2618-A85B-459F-953C-FDE370B152FD

P304

Q34656003-BAE57502-3440-45D9-B1CF-84B04F38A350

P31

Q34656003-6B6EC3A0-093A-4B50-ADE4-6976B4204D59

P356

Q34656003-484AB5D6-C3D6-45B4-BC04-52FC7E907B0E

P407

Q34656003-C137EBF5-3E9E-4C92-B9CA-8F51968135EB

P433

Q34656003-9E6FD76B-FDE4-4CE3-9104-4017447586DC

P478

Q34656003-8D421295-32AC-4FFE-9735-7BF8D396E260

P577

Q34656003-2FF37A76-99BF-479E-A686-CBDE3B078C80

P5875

Q34656003-F7B706BB-9393-4536-A15A-7933E9207D7B

P698

Q34656003-0BC916F6-1CBD-49BC-885B-AEBA48412374

P932

Q34656003-DCF0A4D7-0664-4496-BB49-BE4AB256EEBC

P356

J.ADDR.2007.11.009

P1433

Advanced Drug Delivery Reviews

P1476

Polymer-drug conjugates: recent development in clinical oncology

@en

P2093

Chun Li

http://www.w3.org/2001/XMLSchema#string

Sidney Wallace

http://www.w3.org/2001/XMLSchema#string

P2860

First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.

Pegaspargase: a review of clinical studies

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies

Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate

Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data.

Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.

Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.

Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids.

P304

886-898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ADDR.2007.11.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5479063

http://www.w3.org/2001/XMLSchema#string

P698

18374448

http://www.w3.org/2001/XMLSchema#string

P932

2432086

http://www.w3.org/2001/XMLSchema#string